Digital phenotyping can assess negative symptoms.
Cohen, A. S., Cowan, T., Le, T. P., Schwartz, E. K., Kirkpatrick, B., Raugh, I. M., Chapman, H. C., & Strauss, G. P. (2020). Ambulatory digital phenotyping of blunted affect and alogia using objective facial and vocal analysis: Proof of concept. Schizophrenia Research, 220, 141–146. https://doi.org/10.1016/j.schres.2020.03.043
Cowan, T., Masucci, M. D., Gupta, T., Haase, C. M., Strauss, G. P., & Cohen, A. S. (2022). Computerized analysis of facial expressions in serious mental illness. Schizophrenia Research, 241, 44–51. https://doi.org/10.1016/j.schres.2021.12.026
Cohen, A. S., Fedechko, T. L., Schwartz, E. K., Le, T. P., Foltz, P. W., Bernstein, J., Cheng, J., Holmlund, T. B., & Elvevåg, B. (2019). Ambulatory vocal acoustics, temporal dynamics, and serious mental illness. Journal of Abnormal Psychology, 128(2), 97–105. https://doi.org/10.1037/abn0000397
Promising new passive digital phenotyping measures include acelerometry and geolocation.
Strauss, Gregory, P., Raugh, I. M., Zhang, L., Luther, L., Chapman, H. C., Allen, D. N., Kirkpatrick, B., & Cohen, A. S. (2022). Validation of accelerometry as a digital phenotyping measure of negative symptoms in schizophrenia. Npj Schizophrenia.
Raugh, I. M., James, S. H., Gonzalez, C. M., Chapman, H. C., Cohen, A. S., Kirkpatrick, B., & Strauss, G. P. (2020). Geolocation as a Digital Phenotyping Measure of Negative Symptoms and Functional Outcome. Schizophrenia Bulletin, 46(6), 1596–1607. https://doi.org/10.1093/schbul/sbaa121
Digital phenotyping is well accepted and provides rich information in people with serious mental illness.
Cowan, T., Cohen, A. S., Raugh, I. M., & Strauss, G. P. (2022). Ambulatory audio and video recording for digital phenotyping in schizophrenia: Adherence & data usability. Psychiatry Research, 114485.
Raugh, I. M., James, S. H., Gonzalez, C. M., Chapman, H. C., Cohen, A. S., Kirkpatrick, B., & Strauss, G. P. (2021). Digital phenotyping adherence, feasibility, and tolerability in outpatients with schizophrenia. Journal of Psychiatric Research, 138, 436–443. https://doi.org/10.1016/j.jpsychires.2021.04.022
Digital Phenotyping technologies can be applied to clinical trials.
Cohen, A. S., Mitchell, K. R., Strauss, G. P., Blanchard, J. J., Buchanan, R. W., Kelly, D. L., Gold, J., McMahon, R. P., Adams, H. A., & Carpenter, W. T. (2017). The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study. Schizophrenia Research, 188, 141–143. https://doi.org/10.1016/j.schres.2017.01.028
There are established approaches to validation of digital phenotyping measures.
Cohen, A. S., Cox, C. R., Tucker, R. P., Mitchell, K. R., Schwartz, E. K., Le, T. P., Foltz, P. W., Holmlund, T. B., & Elvevåg, B. (2021). Validating Biobehavioral Technologies for Use in Clinical Psychiatry. Frontiers in Psychiatry, 12. https://doi.org/10.3389/fpsyt.2021.503323
Cohen, A. S., Schwartz, E., Le, T. P., Cowan, T., Kirkpatrick, B., Raugh, I. M., & Strauss, G. P. (2021). Digital phenotyping of negative symptoms: the relationship to clinician ratings. Schizophrenia Bulletin, 47(1), 44–53. https://doi.org/10.1093/schbul/sbaa065
Cohen, A. S. (2019). Advancing ambulatory biobehavioral technologies beyond proof of concept: Introduction to the special section. Psychological Assessment, 31(3), 277–284. https://doi.org/10.1037/pas0000694
Holmlund, T. B., Fedechko, T. L., Elvevåg, B., & Cohen, A. S. (2019). Tracking Language in Real Time in Psychosis. In A Clinical Introduction to Psychosis: Foundations for Clinical Psychologists and Neuropsychologists (pp. 663–685). Academic Press. https://doi.org/10.1016/B978-0-12-815012-2.00028-6
Cohen, A. S., Cox, C. R., Masucci, M. D., Le, T. P., Cowan, T., Coghill, L. M., Holmlund, T. B., & Elvevåg, B. (2020). Digital Phenotyping Using Multimodal Data. Current Behavioral Neuroscience Reports, 7, 212–220. https://doi.org/10.1007/s40473-020-00215-4